A5081313870- Gestational Trophoblastic Disease Studies
- Prenatal Screening and Diagnostics
- Ectopic Pregnancy Diagnosis and Management
- Congenital Diaphragmatic Hernia Studies
- Genetic Syndromes and Imprinting
- Maternal and fetal healthcare
- Pregnancy and preeclampsia studies
- Social Media and Politics
- Lung Cancer Research Studies
- Pharmaceutical Practices and Patient Outcomes
- Neuroendocrine Tumor Research Advances
- Multiple and Secondary Primary Cancers
- Reproductive System and Pregnancy
- Healthcare Systems and Practices
- Osteoarthritis Treatment and Mechanisms
- Knee injuries and reconstruction techniques
- Total Knee Arthroplasty Outcomes
- Pelvic and Acetabular Injuries
- Uterine Myomas and Treatments
- Endometriosis Research and Treatment
- Assisted Reproductive Technology and Twin Pregnancy
- Hip and Femur Fractures
- COVID-19 Impact on Reproduction
- Health Systems, Economic Evaluations, Quality of Life
- Health, Medicine and Society
Hôpital Lyon Sud
2011-2024
Hospices Civils de Lyon
2014-2024
Université Claude Bernard Lyon 1
2010-2021
Centre hospitalier universitaire d'Orléans
2021
Laboratoire National de Référence
2021
HCL Technologies (India)
2020
Institut Français
2015
Université de Lyon
2012
Hôtel-Dieu de Lyon
2005-2010
Women with gestational trophoblastic tumors (GTT) resistant to single-agent chemotherapy receive alternative regimens, which, although effective, cause considerable toxicity. All GTT subtypes express programmed death-ligand 1 (PD-L1), and natural killer (NK) cells are involved in trophoblast immunosurveillance. Avelumab (anti-PD-L1) induces NK cell-mediated cytotoxicity. The TROPHIMMUN trial assessed avelumab women chemotherapy-resistant GTT.In this phase II multicenter (ClinicalTrials.gov...
<h3>Objective</h3> Recently reported expression of programmed cell death 1 ligand (PD-L1) in gestational trophoblastic diseases (GTDs) suggests that the immune tolerance pregnancy might be hijacked during neoplastic process. We assessed PD-L1 protein premalignant and malignant GTD lesions analyzed associations with disease severity chemotherapy outcomes. <h3>Methods</h3> included 83 whole-tissue sections from 76 patients different treatment settings. was immunohistochemistry each trophoblast...
To evaluate the contribution of referent pathologists (RPs) to quality diagnosis trophoblastic diseases and study level diagnostic agreement between initial RPs.This observational retrospective was carried 1 November 1999 11 January 2011 using database French Trophoblastic Disease Reference Centre in Lyon. All files for hydatiform moles (HMs), tumours non-molar pregnancies which there an suspicion disease were included, whenever rereading slides by RP. A total 1851 HMs 150 gestational...
The objective of this study was to evaluate the characteristics and outcomes patients treated for gestational trophoblastic neoplasia (GTN) with second-line 5-day dactinomycin after failed first-line 8-day methotrexate.From 1999 2017, methotrexate resistant GTN second line were identified at French Trophoblastic Disease Reference Center. Using univariate multivariate analysis, we significant predictive factors failure.A total 877 methotrexate, which 103 required failure. Complete response...
The distinction between choriocarcinoma and residual trophoblastic cell proliferation from a complete hydatidiform mole/invasive mole (CHM/IM) without villi is challenging on curettage materials. We investigated whether SALL4 immunostaining could help differentiate various gestational diseases. Placental site nodules (PSN; n=10), atypical PSN (APSN; n=8), placental tumors (PSTT; n=9), epithelioid (ETT; n=5), choriocarcinomas (n=31), partial moles (PHM; n=13), CHM/IM (n=47), nonmolar products...
TPS5636 Background: For patients with rare cancers, there is an unmet medical need to investigate innovative therapeutics beyond standard first-line treatment. These diseases are rarely evaluated in clinical trials. High-risk gestational trophoblastic tumors (GTT) treated polychemotherapy (especially EMA-CO) high cure rate (~95%). However, resistant have a poor prognosis, and no validated regimen has been defined. Several case reports suggest that immune checkpoint inhibitors (ICIs) may be...
Low grade serous ovarian carcinoma (LGSOC) accounts for 2.5% of all more affects younger women than high carcinoma. Hysterectomy is performed routinely LGSOC treatment, but fertility sparring surgery (FSS) feasible some early stages. Currently, there no study about uterine involvement in LGSOC. We evaluate patients and aim to identify pre-operative predictive factors.